CN Patent

CN101835472A — N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法

Assigned to Ambit Bioscience Corp · Expires 2010-09-15 · 16y expired

What this patent protects

本发明提供向人患者给药N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲或其药学上可接受的盐或溶剂化物的方法。特别地，本发明提供剂量给药、剂量给药进程或剂量给药方案。进一步，本发明提供药物制剂。本发明还提供治疗人增殖性疾病或FLT-3介导的疾病的方法。

USPTO Abstract

本发明提供向人患者给药N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲或其药学上可接受的盐或溶剂化物的方法。特别地，本发明提供剂量给药、剂量给药进程或剂量给药方案。进一步，本发明提供药物制剂。本发明还提供治疗人增殖性疾病或FLT-3介导的疾病的方法。

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN101835472A
Jurisdiction: CN
Classification: —
Expires: 2010-09-15
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.